Ann: USA Distribution Partnership for Cellmid's Evolis-CDY.AX, page-96

Thanks Shock, The criticism and concern of long term holders is, despite all that you've listed and more, management has to date failed to implement on Midkine. There is very little rock solid achieved (also reflected in the sp) inome generative, except a peripheral licensing deal; in essence a painful Turnbull scenario ( uum ahh, well, I mean, aah uum, eerr of treading water) but with CDY over a longer period. Fortunately, our success should reult from Evolis alone. [Excuse the unintended underlining]